| 244 | 3 | 37 |
| 下载次数 | 被引频次 | 阅读次数 |
目的分析伏立康唑给药间隔对其疗效和不良反应的影响,以及患者体质量与给药剂量之间的关系。方法通过对1例肺曲霉菌病患者在抗真菌治疗过程中伏立康唑给药间隔和给药剂量调整的分析及药学监护,探讨伏立康唑bid、q12h给药间隔与临床疗效和不良反应的关系,以及超重患者剂量调整的依据。结果伏立康唑依据AUC/MIC评价临床疗效,不受给药间隔影响,但bid给药可引起血药浓度波动,会增加不良反应发生的风险;超重患者按照实际体质量换算给药剂量,剂量偏高,可能导致血药浓度过高,不良反应增加。结论伏立康唑最佳给药间隔为q12h,超重患者按照校正体质量换算给药剂量,取得了满意的治疗效果并避免不良反应的发生。
Abstract：[1] 陈江飞,苗彩云,徐萍,等.抗真菌药伏立康唑的临床药代动力学研究进展[J].中国临床药理学与治疗学,2015,20(9):1072.
[2] SWEET S C.马丁代尔药物大典[M].第37版.李大魁,金有豫,汤光,等,译.第2版.北京:化学工业出版社,2013:523-524.
[3] TROKE P F,HOCKEY H P,HOPE W W,et al.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients[J].Antimicrob Agents Chemother,2011,55(10):4782.
[4] DENNING D W,RIBAUD P,MILPIED N,et al.Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis[J].Clin Infect Dis,2002,34(5):563.
[5] DAVIES-VORBRODT S,ITO J I,TEGTMEIER B R,et al.Voricona-zole serum concentrations in obese and overweight immunocompromised patients:a retrospective review[J].Pharmacotherapy,2013,33(1):22.
[6] WALSH T J,DRISCOLL T,MILLIGAN P A,et al.Pharmacokinetics,safety,and tolerability of voriconazole in immunocompromised children [J].Antimicrob Agents Chemother,2010,54(10):4116.
[7] PFALLER M A,DIEKEMA D J,REX J H,et al.Correlation of MIC with outcome for Candida species tested against voriconazole:analysis and proposal for interpretive breakpoints[J].J Clin Microbiol,2006,44(3):819.
[8] LEPAK A J,ANDES D.Antifungal pharmacokinetics and pharmacodynamics [J].Cold Spring Harb Perspect Med,2014,5(5):a019653.
[9] ANDES D,MARCHILLO K,STAMSTAD T,et al.In vivo pharmacokinetics and pharmacodynamics of a new triazole,voriconazole,in a murine candidiasis model[J].Antimicrob Agents Chemother,2003,47(10):3165.
[10] HAMADA Y,SETO Y,YAGO K,et al.Investigation and threshold of optimum blood concentration of voriconazole:a descriptive statistical meta-analysis [J].J Infect Chemother,2012,18(4):501.
[11] LUONG M L,AL-DABBAGH M,GROLL A H,et al.Utility of voriconazole therapeutic drug montoring:a meta-analysis[J].J Antimicrob Chemother,2016,71(7):1786.
[12] 中国超重/肥胖医学营养治疗专家共识编写委员会.中国超重/肥胖医学营养治疗专家共识(2016版)[J].糖尿病天地(临床),2016,10(9):395.
[13] PAI M P,LODISE T P.Steady-state plasma pharmacokinetics of oral voriconazole in obese adults[J].Antimicrob Agents Chemother,2011,55(6):2601.
[14] KOSELKE E,KRAFT S,SMITH J,et al.Evaluation of the effect of obesity on voriconazole serum concentrations[J].J Antimicrob Chemother,2012,67(12):2957.
[15] 田婷婷,王加林,宋洪涛,等.常见抗菌药物在肥胖人群中剂量换算及临床应用的研究进展[J].中国抗生素杂志,2016,41(12):893.
[16] 王陶陶,孙金钥,陈思颖,等.侵袭性真菌感染患者伏立康唑群体药动学研究及给药方案优化[J].中国药学杂志,2014,49(3):227.
基本信息:
DOI：10.19577/j.1007-4406.2020.03.015
中图分类号:R519
引用信息:
[1]史文秀,叶晓芬,蔡映云,等.1例肺曲霉病患者抗真菌治疗中伏立康唑给药间隔和给药剂量分析[J].中国临床药学杂志,2020,29(03):223-226.DOI:10.19577/j.1007-4406.2020.03.015.
2020-05-25
2020-05-25